Performance in Delivering Clinical Research Q3 2013-14

Time to Target (Commercial Contracts)

Trial Name	Research Ethics Committee Number	Target number of patients	Recruitment end date	Trial Status	Target met?	Comments
RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics - Protocol No. NN25310	10/H0606/69	6	08/05/2013	Closed – in follow up	No	Four participants recruited from six, viewed as successful by the sponsor because this study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious
RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics. Protocol No. NN25307	10/H0604/94	6	30/06/2013	Closed – in follow up	No	Again this study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious
Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy male and female volunteers.	11/SC/0383	64	15/05/2013	Closed – follow up complete	Yes	
Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of LuAA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls	12/SC/0213	32	31/07/2013	Closed – follow up complete	No	30 participants were recruited. The study team were unable to recruit the final 2 controls and another UK site (Manchester) agreed to do this. The study recruited the target in the UK. 30 participants of 32 recruited equals 94%.
A randomised, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS) in non-smokers	12/SC/0544	3	03/01/2014	Open	N/A	
A randomised, placebo-controlled, parallel-group, double-blind, efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's Disease (EPOCH)	12/NE/0410	8	31/08/2015	Open	N/A	
A randomised, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of once a day, TAK-375 (Ramelteon) tablet for sublingual administration (TAK-375SL tablet) 0.1mg and 0.4mg as an adjunctive therapy in the treatment of acute depressive episodes associated with bipolar 1 disorder in adult subjects	12/EM/0391	5	20/07/2014	Open	N/A	